Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 10/20 | 0.43 |
| ▸ | HRH1 | P35367 | 4/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.39 |
| ▸ | HTR2B | P41595 | 3/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.39 |
| ▸ | SLC22A1 | O15245 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | HTR1A | P08908 | 2/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.39 |
| ▸ | DRD1 | P21728 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pirandamine SCHEMBL120083 | 0.99 | UTS2R (0.45) | UTS2RHRH1SLC6A2CHRM2CHRM4 | |
| SCHEMBL11767108 | 0.93 | LMNA (0.44) | UTS2RHRH1SLC6A2CHRM2CHRM4 | |
| Hydrochloric Acid SCHEMBL11766996 | 0.91 | LMNA (0.43) | UTS2RHRH1SLC6A2CHRM2CHRM4 | |
| SCHEMBL11772576 | 0.88 | SIGMAR1 (0.39) | UTS2RHRH1SLC6A2CHRM2CHRM4 | |
| SCHEMBL11767677 | 0.87 | SLC6A2 (0.35) | UTS2RHRH1SLC6A2CHRM2CHRM4 | |
| Hydrochloric Acid SCHEMBL11771572 | 0.86 | SLC6A2 (0.36) | UTS2RHRH1SLC6A2CHRM2CHRM4 | |
| SCHEMBL11769642 | 0.84 | CHRM2 (0.35) | SLC6A2CHRM2CHRM1KCNH2HTR1A | |
| SCHEMBL11767690 | 0.84 | CHRM2 (0.35) | SLC6A2CHRM2CHRM1KCNH2HTR1A | |
| SCHEMBL11767726 | 0.82 | UTS2R (0.42) | UTS2RHRH1SLC6A2CHRM2CHRM4 | |
| SCHEMBL11772330 | 0.82 | HTR1A (0.34) | HRH1SLC6A2CHRM2CHRM1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 364 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12514883-B2 | Compositions and methods for modulating lipid and steroid metabolism | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-01-06 | — | — | US | claimed |
| EP-4536231-A1 | TREATMENT OF ANTIDEPRESSANT RESISTANT SUBJECTS | Actinogen Medical Limited (AU) | 2025-04-16 | — | — | EP | claimed |
| US-20240307393-A1 | PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION OR TREATMENT, COMPRISING CDK4/6 INHIBITOR AND TRICYCLIC ANTIDEPRESSANT | NATIONAL CANCER CENTER (KR) | 2024-09-19 | — | — | US | claimed |
| EP-4368183-A1 | PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION OR TREATMENT, COMPRISING CDK4/6 INHIBITOR AND TRICYCLIC ANTIDEPRESSANT | National Cancer Center (KR) | 2024-05-15 | — | — | EP | claimed |
| CN-117597126-A | Pharmaceutical composition for preventing or treating cancer comprising CDK4/6 inhibitor and tricyclic antidepressant | 国立癌症中心 | 2024-02-23 | — | — | CN | claimed |
| WO-2023235937-A1 | TREATMENT OF ANTIDEPRESSANT RESISTANT SUBJECTS | Actinogen Medical Limited (AU) | 2023-12-14 | — | — | WO | claimed |
| US-20230381168-A1 | ADJUNCTIVE THERAPY FOR DEPRESSION | ANEUROTECH BV (BE) | 2023-11-30 | — | — | US | claimed |
| US-11794009-B2 | Devices, systems and methods for treating urological and gastrointestinal disorders by electrical stimulation of the foot | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2023-10-24 | — | — | US | claimed |
| WO-2023282544-A1 | PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION OR TREATMENT, COMPRISING CDK4/6 INHIBITOR AND TRICYCLIC ANTIDEPRESSANT | 국립암센터 | 2023-01-12 | — | — | WO | claimed |
| US-20220265641-A1 | SEROTONERGIC AGENT AND 5-HT1A-RECEPTOR ANTAGONIST | ATLAS PHARMACEUTICALS BV (BE) | 2022-08-25 | — | — | US | claimed |
| EP-1353675-A2 | NEW DRUG COMBINATIONS OF NOREPINEHRINE REUPTAKE INHIBITORS AND NEUROLEPTIC AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2003-10-22 | — | — | EP | claimed |
| CN-1396829-A | Novel pharmaceutical combination | PHARMACIA & UPJOHN (US) | 2003-02-12 | — | — | CN | claimed |
| EP-1257277-A2 | NEW DRUG COMBINATIONS COMPRISING A NOREPINEPHRINE REUPTAKE INHIBITOR AND AN ANTIMUSCARINIC AGENT | PHARMACIA & UPJOHN COMPANY (US) | 2002-11-20 | — | — | EP | claimed |
| US-20020156067-A1 | New drug combinations | PHARMACIA & UPJOHN COMPANY | 2002-10-24 | — | — | US | claimed |
| WO-2002053140-A2 | NEW DRUG COMBINATIONS OF NOREPINEHRINE REUPTAKE INHIBITORS AND NEUROLEPTIC AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2002-07-11 | — | — | WO | claimed |
| US-20020010216-A1 | New drug combinations | PHARMACIA & UPJOHN COMPANY | 2002-01-24 | — | — | US | claimed |
| WO-2001062236-A2 | NEW DRUG COMBINATIONS COMPRISING A NOREPINEPHRINE REUPTAKE INHIBITOR AND AN ANTIMUSCARINIC AGENT | PHARMACIA & UPJOHN COMPANY (US) | 2001-08-30 | — | — | WO | claimed |
| WO-1997041878-A1 | TREATMENT OF MOOD DISORDERS WITH A GROWTH HORMONE SECRETAGOGUE | MERCK & CO., INC. (US) | 1997-11-13 | — | — | WO | claimed |
| EP-0174342-B1 | BRAIN-SPECIFIC ANALOGUES OF CENTRALLY ACTING AMINES | UNIVERSITY OF FLORIDA (US) | 1989-12-20 | — | — | EP | claimed |
| US-3995052-A | Indenopyran- and indenothiopyranalkylamines III in the treatment of depression | AYERST MCKENNA AND HARRISON LTD. (CA) | 1976-11-30 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220265641-A1 | SEROTONERGIC AGENT AND 5-HT1A-RECEPTOR ANTAGONIST | HTR5A, HTR1A, HTR4 | UTS2R 381/4885HRH1 475/4885SLC6A2 111/4885 |
| US-20230381168-A1 | ADJUNCTIVE THERAPY FOR DEPRESSION | HTR2A, HTR3B, HTR5A | UTS2R 499/4885HRH1 255/4885SLC6A2 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.